[{"address1": "2155 Park Boulevard", "city": "Palo Alto", "state": "CA", "zip": "94306", "country": "United States", "phone": "650 272 6138", "fax": "650 618 1621", "website": "https://www.eigerbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.", "fullTimeEmployees": 25, "auditRisk": 8, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 10.0, "open": 10.1, "dayLow": 10.0, "dayHigh": 10.7, "regularMarketPreviousClose": 10.0, "regularMarketOpen": 10.1, "regularMarketDayLow": 10.0, "regularMarketDayHigh": 10.7, "beta": 2.106, "forwardPE": -2.8333333, "volume": 23493, "regularMarketVolume": 23493, "averageVolume": 123887, "averageVolume10days": 41080, "averageDailyVolume10Day": 41080, "bid": 9.94, "ask": 10.79, "bidSize": 40000, "askSize": 40000, "marketCap": 15104160, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 28.5, "priceToSalesTrailing12Months": 0.9575959, "fiftyDayAverage": 2.81646, "twoHundredDayAverage": 6.67317, "currency": "USD", "enterpriseValue": 30596402, "floatShares": 1227670, "sharesOutstanding": 1480800, "sharesShort": 29810, "sharesShortPriorMonth": 41440, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0201, "heldPercentInsiders": 0.14774, "heldPercentInstitutions": 0.30525, "shortRatio": 1.6, "shortPercentOfFloat": 0.028499998, "impliedSharesOutstanding": 1579080, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -74963000, "forwardEps": -3.6, "lastSplitFactor": "1:30", "lastSplitDate": 1704672000, "enterpriseToRevenue": 1.94, "enterpriseToEbitda": -0.428, "52WeekChange": -0.5674653, "SandP52WeekChange": 0.26238096, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "EIGRQ", "underlyingSymbol": "EIGRQ", "shortName": "Eiger BioPharmaceuticals, Inc.", "longName": "Eiger BioPharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1391092200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "db3d2481-ac37-3b26-bcbc-7a221a994156", "messageBoardId": "finmb_52776077", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.2, "targetHighPrice": 30.0, "targetLowPrice": 30.0, "targetMeanPrice": 30.0, "targetMedianPrice": 30.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 25844000, "totalCashPerShare": 17.453, "ebitda": -71511000, "totalDebt": 41203000, "quickRatio": 0.517, "currentRatio": 0.71, "totalRevenue": 15773000, "revenuePerShare": 10.685, "returnOnAssets": -0.56448, "returnOnEquity": -3.6699798, "freeCashflow": -53257500, "operatingCashflow": -74548000, "revenueGrowth": 0.411, "grossMargins": 0.99848, "operatingMargins": -3.31686, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]